383 related articles for article (PubMed ID: 33450197)
1. Targeting pan-essential genes in cancer: Challenges and opportunities.
Chang L; Ruiz P; Ito T; Sellers WR
Cancer Cell; 2021 Apr; 39(4):466-479. PubMed ID: 33450197
[TBL] [Abstract][Full Text] [Related]
2. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
[TBL] [Abstract][Full Text] [Related]
3. Progress and challenges towards targeted delivery of cancer therapeutics.
Rosenblum D; Joshi N; Tao W; Karp JM; Peer D
Nat Commun; 2018 Apr; 9(1):1410. PubMed ID: 29650952
[TBL] [Abstract][Full Text] [Related]
4. Potential Successes and Challenges of Targeted Cancer Therapies.
Keefe DMK; Bateman EH
J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425592
[TBL] [Abstract][Full Text] [Related]
5. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
6. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer therapies.
Yan L; Rosen N; Arteaga C
Chin J Cancer; 2011 Jan; 30(1):1-4. PubMed ID: 21192839
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
9. Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics.
Choi SH; Shah K
Discov Med; 2016 Sep; 22(120):157-166. PubMed ID: 27755970
[TBL] [Abstract][Full Text] [Related]
10. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
Pagliarini R; Shao W; Sellers WR
EMBO Rep; 2015 Mar; 16(3):280-96. PubMed ID: 25680965
[TBL] [Abstract][Full Text] [Related]
11. Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.
Rudd SG
Cancer Chemother Pharmacol; 2023 Oct; 92(4):241-251. PubMed ID: 37452860
[TBL] [Abstract][Full Text] [Related]
12. Clinical advances in targeting epigenetics for cancer therapy.
Feng S; De Carvalho DD
FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine and the rapidly approaching future of cancer management.
Markman M
Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP207-8, cover. PubMed ID: 23301708
[No Abstract] [Full Text] [Related]
14. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
[TBL] [Abstract][Full Text] [Related]
15. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges.
Workman P
Curr Cancer Drug Targets; 2001 May; 1(1):33-47. PubMed ID: 12188890
[TBL] [Abstract][Full Text] [Related]
16. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
[TBL] [Abstract][Full Text] [Related]
17. Recent development of anticancer therapeutics targeting Akt.
Morrow JK; Du-Cuny L; Chen L; Meuillet EJ; Mash EA; Powis G; Zhang S
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):146-59. PubMed ID: 21110830
[TBL] [Abstract][Full Text] [Related]
18. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
19. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
Bao J; Qiao L
Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
[No Abstract] [Full Text] [Related]
20. Structural And Computational Perspectives of Selectively Targeting Mutant Proteins.
Coban MA; Fraga S; Caulfield TR
Curr Drug Discov Technol; 2021; 18(3):365-378. PubMed ID: 32160847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
